Remoxipride and haloperidol in schizophrenia: a double-blind multicentre study
| Autor: | H. Rantanen, A. Sorri, J. Outakoski, E. Tolvanen, T. Tamminen, U. G. Ahlfors, A.-C. Holm, Björn Appelberg, Hannu Naukkarinen, U. Hagert, Heikki Katila, O-P. Mehtonen, Ranan Rimón, P. Harma, A. Mahlanen |
|---|---|
| Rok vydání: | 1990 |
| Předmět: |
Adult
Male Dyskinesia Drug-Induced medicine.medical_specialty Adolescent Double blind 03 medical and health sciences 0302 clinical medicine Double-Blind Method Extrapyramidal symptoms Brief Psychiatric Rating Scale medicine Haloperidol Remoxipride Humans Psychiatry Aged Neurologic Examination Psychiatric Status Rating Scales Dose-Response Relationship Drug Middle Aged medicine.disease 030227 psychiatry 3. Good health Discontinuation Psychiatry and Mental health Schizophrenia Anesthesia Benzamides Clinical Global Impression Female Schizophrenic Psychology medicine.symptom Psychology 030217 neurology & neurosurgery Antipsychotic Agents medicine.drug |
| Zdroj: | Acta Psychiatrica Scandinavica. 82:99-103 |
| ISSN: | 1600-0447 0001-690X |
| DOI: | 10.1111/j.1600-0447.1990.tb05298.x |
| Popis: | Ninety-two patients with schizophrenia were included in a double-blind multicentre parallel-group trial comparing remoxipride and haloperidol. The mean daily dose during the last week of treatment was 316 mg (range, 150-600 mg) in the remoxipride group and 8.7 mg (range, 5-20 mg) in the haloperidol group. The study period was six weeks with at least one day of washout. Both Clinical Global Impression (CGI) rating, and Brief Psychiatric Rating Scale (BPRS) total scores declined at the end of the trial compared with pretreatment values in both groups. No significant differences were found between the remoxipride and haloperidol groups with regard to the treatment outcome. Treatment-emergent extrapyramidal symptoms were statistically more frequent and more severe during haloperidol than during remoxipride treatment. Haloperidol-treated patients reported also significantly more concentration difficulties. Severe extrapyramidal side effects in the haloperidol group and clinical ineffectiveness in the remoxipride group were the most frequent reasons for premature discontinuation of treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text